Market Place
Sourcing Support
Rhythm Pharma Reports Q3 2024 Financial Results & Business Update
05 Nov 2024 //
GLOBENEWSWIRE
Rhythm And Axovia Announce Collaboration In Bardet-Biedl Syndrome
24 Oct 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
09 Oct 2024 //
GLOBENEWSWIRE
Rhythm Pharma to Present at Wells Fargo Healthcare Conference in September
26 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharma Announces FDA Priority Review for IMCIVREE® for Patients Aged 2+
26 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals To Present At Wells Fargo Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
FDA Accepts Rhythm`s sNDA For IMCIVREE In Patients As Young As 2 Years Old
26 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
13 Aug 2024 //
GLOBENEWSWIRE
Rhythm Pharma`s IMCIVREE® Approved For Children 2+ In Europe
31 Jul 2024 //
GLOBENEWSWIRE
Rhythm To Report Q2 2024 Results On August 6
23 Jul 2024 //
GLOBENEWSWIRE
Rhythm Pharma Receives Positive CHMP Opinion For IMCIVREE In Young Children
28 Jun 2024 //
GLOBENEWSWIRE
NICE recommends Rhythm’s Imcivree for rare genetic obesity disorder
22 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Rhythm Pharmaceuticals Q1 2024 Results And Business Update
07 May 2024 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide
22 Feb 2024 //
GLOBENEWSWIRE
Rhythm Pharma Announces Positive Reimbursement Decision in Italy for IMCIVREE
07 Feb 2024 //
GLOBENEWSWIRE
Rhythm Announces Completion of Screening for Enrollment in Setmelanotide Trial
04 Jan 2024 //
GLOBENEWSWIRE
Rhythm Receives Positive CADTH Reimbursement Recommendation for IMCIVREE
02 Nov 2023 //
GLOBENEWSWIRE
Rhythm Presents Data from its Long-term Extension Study of Setmelanotide
17 Oct 2023 //
GLOBENEWSWIRE
Rhythm Receives Orphan Drug Designation from EMA for Setmelanotide
19 Sep 2023 //
GLOBENEWSWIRE
Rhythm Announces Pre-Marketing Early Access Authorization for Setmelanotide
07 Aug 2023 //
GLOBENEWSWIRE
Imcivree causes weight loss in patients with hypothalamic obesity
19 Jun 2023 //
CLINICAL TRIALS ARENA
Rhythm and Genpharm Announce Collaboration to Provide IMCIVREE
22 May 2023 //
GLOBENEWSWIRE
Rhythm Pharma Announces Health Canada Approval of IMCIVREE® Setmelanotide
08 May 2023 //
GLOBENEWSWIRE
Rhythm Announces Commercial Launch of IMCIVREEÂ
24 Apr 2023 //
GLOBENEWSWIRE
Rhythm Announces IMCIVREE Granted Marketing Authorization in Great Britain
22 Nov 2022 //
NASDAQ
Rhythm Announces IMCIVREE Granted Marketing Authorization in Great Britain
21 Nov 2022 //
PRESS RELEASE
Rhythm Announces Publication of Results from Ph3 Clinical Trial of IMCIVREE®
08 Nov 2022 //
GLOBENEWSWIRE
Rhythm to Present Full Data from Phase 2 Trial Evaluating Setmelanotide
25 Oct 2022 //
GLOBENEWSWIRE
Rhythm Presents New Disease Burden Findings and Analyses of Setmelanotide Data
19 Sep 2022 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide)
06 Sep 2022 //
GLOBENEWSWIRE
Rhythm Pharma Announces Early Access Authorization for Setmelanotide
20 Jul 2022 //
GLOBENEWSWIRE
Rhythm Pharma Launches IMCIVREE in Germany for Obesity and Control of Hunger
22 Jun 2022 //
GLOBENEWSWIRE
Rhythm`s Imcivree Scores FDA Approval in Bardet-Biedl Syndrome
17 Jun 2022 //
BIOSPACE
Rhythm Pharma Presents New Data from Phase 3 Trial Evaluating Setmelanotide
02 May 2022 //
GLOBENEWSWIRE
Rhythm Pharma Optimizes Design of two Trials to Advance Setmelanotide
06 Apr 2022 //
GLOBENEWSWIRE
Rhythm Pharma Announces FDA Extension of Review Period for IMCIVREE
24 Feb 2022 //
GLOBENEWSWIRE
Rhythm Pharma Announces Positive Interim Data from Study of Setmelanotide in BBS
16 Feb 2022 //
GLOBENEWSWIRE
Rhythm Begins Dosing in DAYBREAK and Weekly Trials Evaluating Setmelanotide
13 Jan 2022 //
GLOBENEWSWIRE
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review
15 Nov 2021 //
GLOBENEWSWIRE
Rhythm Completes Submission of Type II Variation Application to EMA IMCIVREE®
14 Oct 2021 //
GLOBENEWSWIRE
Rhythm Pharma Completes Submission of Supplemental NDA to USFDA for IMCIVREE
20 Sep 2021 //
GLOBENEWSWIRE
Rhythm Announces Expanded Access Program for Setmelanotide in BBS
08 Sep 2021 //
GLOBENEWSWIRE
Uncovering the secret of the hunger switch in the brain
19 Apr 2021 //
SCIENCE DAILY
Rhythm Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss
22 Mar 2021 //
GLOBENEWSWIRE
Rhythm ph 3 trial of setmelanotide to treat Bardet-Biedl & Alström syndromes
23 Dec 2020 //
PHARMABIZ
Rhythm Pharma’s phase 3 trial of setmelanotide to treat Bardet-Biedl
23 Dec 2020 //
PHARMABIZ
Rhythm Announces FDA Approval of IMCIVREE™ (setmelanotide)
27 Nov 2020 //
GLOBENEWSWIRE
FDA Grants Rhythm Rare Pediatric Disease Designation for Rare Obesities Drug
02 Jul 2020 //
GLOBALNEWS
Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study
24 Jun 2020 //
GLOBENEWSWIRE
EMA Considers Fast-Tracking Rhythm’s Insatiable Hunger & Obesity Disorders Drug
30 Apr 2020 //
PINK
As Rhythm Pharmaceuticals preps for first approval, CEO hits the exit
08 Jan 2020 //
FIERCE BIOTECH
Rhythm Pharma gets orphan status for setmelanotide
19 Sep 2019 //
SEEKINGALPHA
